+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Bronchitis Drugs Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

  • PDF Icon


  • 156 Pages
  • February 2024
  • Region: Global
  • Infogence Global Research
  • ID: 5684283

According to Cdc, 5% of the Adults in the Us Were Diagnosed With Chronic Obstructive Pulmonary Disease (Copd), Emphysema, or Chronic Emphysema in 2020

The Global Bronchitis Drugs Market is estimated to be USD 1.55 Bn in 2023 and is expected to reach USD 2.41 Bn by 2028 growing at a CAGR of 9.21%.

Market Dynamics

Market dynamics are forces that impact the prices and behaviors of the Global Bronchitis Drugs Market stakeholders. These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service. Forces of Market Dynamics may be related to macro-economic and micro-economic factors. There are dynamic market forces other than price, demand, and supply. Human emotions can also drive decisions, influence the market, and create price signals.

As the market dynamics impact the supply and demand curves, decision-makers aim to determine the best way to use various financial tools to stem various strategies for speeding the growth and reducing the risks.

Market Segmentations

  • The Global Bronchitis Drugs Market is segmented based on Drug Type, Application, End-User, and Geography.
  • By Drug Type, the market is classified into Anti-inflammatory Drugs, Antibiotics, Bronchodilators, and Mucolytics.
  • By Application, the market is classified into Acute Bronchitis and Chronic Bronchitis.
  • By End-User, the market is classified into Hospital Pharmacies and Retail Pharmacies.
  • By Geography, the market is classified into Americas, Europe, Middle-East & Africa, and Asia-Pacific.

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are Boehringer Ingelheim International GmbH, Pfizer Inc., Bayer Ag, Sanofi S.A., Dr. Reddy's Laboratories Inc., Teva Pharmaceuticals USA, Inc., Aurobindo Pharma Ltd., Fresenius Kabi USA, LLC, GSK PLC, etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

  • The report presents a detailed Ansoff matrix analysis for the Global Bronchitis Drugs Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.
  • The publisher analyses the Global Bronchitis Drugs Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • Based on the SWOT analysis conducted on the industry and industry players, the publisher has devised suitable strategies for market growth.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Bronchitis Drugs Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter's 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains the competitive analysis using Positioning Quadrants, the Proprietary competitive positioning tool.

Report Highlights:

  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations, and Outlook
4 Market Dynamics
4.1 Drivers
4.1.1 Increasing Incidences of Respiratory Problems in the Growing Elderly Population
4.1.2 Growing Unhealthy Habits such as Smoking Among the Population
4.1.3 Expansion of Industries Increases the Incidence of Chronic Bronchitis
4.2 Restraints
4.2.1 High Cost of Investment in the Production of Bronchitis Drugs
4.3 Opportunities
4.3.1 Increasing Investments from Government and Private Organizations for Research and Development of Bronchitis Drugs
4.3.2 Growing Strategic Collaborations Among Manufacturers
4.4 Challenges
4.4.1 Strict Regulations and Cumbersome Procedure in the Approval Process
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis
6 Global Bronchitis Drugs Market, By Drug Type
6.1 Introduction
6.2 Anti-inflammatory Drugs
6.3 Antibiotics
6.4 Bronchodilators
6.5 Mucolytics
7 Global Bronchitis Drugs Market, By Application
7.1 Introduction
7.2 Acute Bronchitis
7.3 Chronic Bronchitis
8 Global Bronchitis Drugs Market, By End-User
8.1 Introduction
8.2 Hospital Pharmacies
8.3 Retail Pharmacies
9 Americas’ Bronchitis Drugs Market
9.1 Introduction
9.2 Argentina
9.3 Brazil
9.4 Canada
9.5 Chile
9.6 Colombia
9.7 Mexico
9.8 Peru
9.9 United States
9.10 Rest of Americas
10 Europe’s Bronchitis Drugs Market
10.1 Introduction
10.2 Austria
10.3 Belgium
10.4 Denmark
10.5 Finland
10.6 France
10.7 Germany
10.8 Italy
10.9 Netherlands
10.10 Norway
10.11 Poland
10.12 Russia
10.13 Spain
10.14 Sweden
10.15 Switzerland
10.16 United Kingdom
10.17 Rest of Europe
11 Middle East and Africa’s Bronchitis Drugs Market
11.1 Introduction
11.2 Egypt
11.3 Israel
11.4 Qatar
11.5 Saudi Arabia
11.6 South Africa
11.7 United Arab Emirates
11.8 Rest of MEA
12 APAC’s Bronchitis Drugs Market
12.1 Introduction
12.2 Australia
12.3 Bangladesh
12.4 China
12.5 India
12.6 Indonesia
12.7 Japan
12.8 Malaysia
12.9 Philippines
12.10 Singapore
12.11 South Korea
12.12 Sri Lanka
12.13 Thailand
12.14 Taiwan
12.15 Rest of Asia-Pacific
13 Competitive Landscape
13.1 Competitive Quadrant
13.2 Market Share Analysis
13.3 Strategic Initiatives
13.3.1 M&A and Investments
13.3.2 Partnerships and Collaborations
13.3.3 Product Developments and Improvements
14 Company Profiles
14.1 Apotex Inc.
14.2 Boehringer Ingelheim International GmbH
14.3 Pfizer Inc.
14.4 Bayer Ag
14.5 Sanofi S.A.
14.6 Dr. Reddy's Laboratories Inc.
14.7 Teva Pharmaceuticals USA, Inc.
14.8 West-Ward Pharmaceuticals Corp. (Hikma Pharmaceuticals USA)
14.9 NorthStar Rx LLC
14.10 Aurobindo Pharma Ltd.
14.11 Lupin Pharmaceuticals, Inc.
14.12 Fresenius Kabi USA, LLC
14.13 GSK PLC
14.14 Novartis Ag
14.15 Adel
14.17 Major Pharmaceuticals, Inc.
14.18 Lupin Ltd.
15 Appendix
15.1 Questionnaire

Companies Mentioned

  • Apotex Inc.
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc.
  • Bayer Ag
  • Sanofi S.A.
  • Dr. Reddy's Laboratories Inc.
  • Teva Pharmaceuticals USA, Inc.
  • West-Ward Pharmaceuticals Corp. (Hikma Pharmaceuticals USA)
  • NorthStar Rx LLC
  • Aurobindo Pharma Ltd.
  • Lupin Pharmaceuticals, Inc.
  • Fresenius Kabi USA, LLC
  • Novartis Ag
  • Adel
  • Major Pharmaceuticals, Inc.
  • Lupin Ltd.

Table Information